{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:17:09Z","timestamp":1790788629555,"version":"4.1.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the frequency distribution of KRAS mutant subtypes in patients with resectable PDAC in China and then evaluate the prognostic value of different KRAS subtypes in patients with PDAC undergoing radical resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinicopathological data and gene test reports of 227 patients undergoing PDAC radical surgery at Hunan Provincial People\u2019s Hospital from 1 January 2016 to 1 January 1 2020 were retrospectively evaluated. There were 118 men (52%) and 109 women (48%). The mean age was 58.8 \u00b1 10.3 years. After univariate analysis of the clinicopathological factors (sex, age, presence or absence of underlying disease, location of the primary tumour, tumour TNM stage, T stage, N stage, presence or absence of vascular invasion, presence or absence of nerve invasion, surgical margin, KRAS mutation subtype), variables with P &amp;lt; 0.1 were included in the multivariate Cox regression model analysis, and the log-rank sum test and Kaplan\u2212Meier curves were used to assess the correlation of the KRAS mutation subtype with the overall survival time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>KRAS mutations were detected in 184 of 227 patients (81.1%) (G12D: 66; G12V: 65; G12R: 27; Q61:26) and were not detected in 43 patients (18.9%). KRAS mutations were associated with tumour differentiation (P = 0.001), TNM stage (P = 0.013), and T stage (P &amp;lt; 0.001). Multivariate Cox regression model analysis showed that N stage, surgical margin, tumour differentiation, and KRAS-G12D mutation were independent prognostic factors for DFS and OS. Patients with the KRAS-G12D subtype had shorter OS with a median OS of 12 months (HR: 0.55, CI: 0.39\u20130.77, P &amp;lt; 0.001), and patients with KRAS wild-type had longer OS with a median OS of 19 months (HR: 0.57, CI: 0.42\u20130.76, P &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>KRAS wild-type individuals are more prevalent in the Chinese population than in European or American populations. Patients undergoing surgery had a reduced percentage of tumors with KRAS-G12D. When determining the prognosis of individuals with radically resected PDAC, reference markers for KRAS mutation subtypes can be employed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1074538","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:42:48Z","timestamp":1670938968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection"],"prefix":"10.3389","volume":"12","author":[{"given":"Manxiong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Jahanzaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: A secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00642443","article-title":"Laparoscopic pylorus-preserving pancreatoduodenectomy","volume":"8","author":"Gagner","year":"1994","journal-title":"Surg Endosc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020309","article-title":"From genetic alterations to tumor microenvironment: The ariadne\u2019s string in pancreatic cancer","volume":"9","author":"Bazzichetto","year":"2020","journal-title":"Cells"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Cancer Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"B9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2013.12.004","article-title":"KRAS: feeding pancreatic cancer proliferation","volume":"39","author":"Bryant","year":"2014","journal-title":"Trends Biochem Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: The devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193175","article-title":"KRAS G12D mutation subtype in pancreatic ductal adenocarcinoma: Does it influence prognosis or stage of disease at presentation","volume":"11","author":"Shen","year":"2022","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0767-4","article-title":"KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer","volume":"48","author":"Boeck","year":"2013","journal-title":"J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31825b6ab0","article-title":"Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival","volume":"42","author":"Shin","year":"2013","journal-title":"Pancreas"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0664-2","article-title":"Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer","volume":"48","author":"Ogura","year":"2013","journal-title":"J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"103897","DOI":"10.1016\/j.ebiom.2022.103897","article-title":"Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer","volume":"77","author":"Zhang","year":"2022","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1101\/gad.275776.115","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"30","author":"Ying","year":"2016","journal-title":"Genes Dev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-455","article-title":"KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples","volume":"9","author":"Loong","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1593\/neo.04445","article-title":"Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis","volume":"7","author":"L\u00f6hr","year":"2005","journal-title":"Neoplasia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/138920211794520132","article-title":"Genetic and epigenetic alterations in pancreatic carcinogenesis","volume":"12","author":"Delpu","year":"2011","journal-title":"Curr Genomics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12885-022-09279-9","article-title":"The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0275","article-title":"Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine","volume":"8","author":"Aguirre","year":"2018","journal-title":"Cancer Discovery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx343","article-title":"Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study","volume":"28","author":"Schultheis","year":"2017","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","author":"Singhi","year":"2019","journal-title":"Gastroenterology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3679","article-title":"Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes","volume":"10","author":"Lu","year":"2021","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00418-1","article-title":"Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data","volume":"22","author":"Connor","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1074538\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:42:51Z","timestamp":1670938971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1074538\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":32,"alternative-id":["10.3389\/fonc.2022.1074538"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1074538","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"1074538"}}